Shareholders back PMV Pharmaceuticals (NASDAQ: PMVP) board, pay plans

Rhea-AI Filing Summary

PMV Pharmaceuticals, Inc. reported the results of its 2026 virtual annual meeting of stockholders. Stockholders elected two Class III directors: David H. Mack, Ph.D. received 15,693,907 votes for and 6,248,461 withheld, while Laurie Stelzer received 11,261,111 votes for and 10,681,257 withheld. Each will serve until the 2029 annual meeting, subject to earlier death, resignation or removal.

Stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 15,015,578 votes for, 6,468,718 against, 458,072 abstentions and 6,975,412 broker non-votes. They also ratified the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, by 28,379,108 votes for, 536,302 against and 2,370 abstentions.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Votes for David H. Mack, Ph.D.: 15,693,907 votes Votes for Laurie Stelzer: 11,261,111 votes Say-on-pay votes for: 15,015,578 votes +3 more

6 metrics

Votes for David H. Mack, Ph.D. 15,693,907 votes Election as Class III director at 2026 annual meeting

Votes for Laurie Stelzer 11,261,111 votes Election as Class III director at 2026 annual meeting

Say-on-pay votes for 15,015,578 votes Non-binding advisory approval of executive compensation

Say-on-pay votes against 6,468,718 votes Non-binding advisory executive compensation vote

Auditor ratification votes for 28,379,108 votes Ratification of Ernst & Young LLP for fiscal year 2026

Auditor ratification votes against 536,302 votes Ratification of Ernst & Young LLP for fiscal year 2026

Key Terms

non-binding advisory vote, broker non-vote, independent registered public accounting firm, emerging growth company, +1 more

5 terms

non-binding advisory vote financial

"The Company’s stockholders approved, on a non-binding advisory basis, the compensation paid to its named executive officers"

A non-binding advisory vote is a shareholder vote that expresses investors’ opinion on a proposal (such as executive pay, corporate policy, or governance practices) but does not legally force the company to act. Think of it like a customer survey: it signals whether owners approve or disapprove and can pressure boards and managers to change course, so investors watch the result as an indicator of governance risk and potential future shifts in company strategy or leadership.

broker non-vote financial

"FOR | | AGAINST | | ABSTAIN | | BROKER NON-VOTE 15,015,578 | | 6,468,718 | | 458,072 | | 6,975,412"

independent registered public accounting firm financial

"Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

emerging growth company regulatory

"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Audit Committee financial

"ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP"

A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

false 0001699382 0001699382 2026-06-04 2026-06-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

June 4, 2026

PMV Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39539		46-3218129
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

400 Alexander Park Drive, Suite 301 Princeton, New Jersey		08540
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (609) 642-6670

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		PMVP		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 4, 2026, PMV Pharmaceuticals, Inc. (the “Company”) held its virtual 2026 Annual Meeting of Stockholders (the “Annual Meeting”) exclusively online via live webcast. The stockholders voted on the following proposals at the Annual Meeting:

Proposal 1. Election of Directors

The Company’s stockholders elected the two persons listed below as Class III Directors, each to serve until the Company’s 2029 annual meeting of stockholders and until their respective successors has been duly elected and qualified, or until the earlier of the respective director’s death, resignation or removal. The final voting results are as follows:

		FOR		WITHHELD		BROKER NON-VOTE
David H. Mack, Ph.D.		15,693,907		6,248,461		6,975,412
Laurie Stelzer		11,261,111		10,681,257		6,975,412

Proposal 2. Non-Binding Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers

The Company’s stockholders approved, on a non-binding advisory basis, the compensation paid to its named executive officers as described in the Company’s definitive proxy statement on Schedule 14A, filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 22, 2026 (the “Proxy Statement”). The final voting results are as follows:

FOR		AGAINST		ABSTAIN		BROKER NON-VOTE
15,015,578		6,468,718		458,072		6,975,412

Consistent with the recommendation of the Company’s Board of Directors and based on the Company’s stockholders’ approval at the Company’s 2022 annual meeting of stockholders, held on June 2, 2022, the Company conducts non-binding advisory votes on the compensation of its named executive officers every year. This policy will remain in effect until the next non-binding advisory stockholder vote on the frequency of future stockholder advisory votes on the compensation of the Company’s named executive officers, expected to be held at the Company’s 2028 annual meeting of stockholders.

Proposal 3. Ratification of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:

FOR		AGAINST		ABSTAIN
28,379,108		536,302		2,370

For more information about the foregoing proposals, see the Proxy Statement as filed with the SEC.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PMV PHARMACEUTICALS, INC.
By:		/s/ Michael Carulli
		Michael Carulli
		Chief Financial Officer

Date: June 5, 2026

FAQ

What did PMV Pharmaceuticals (PMVP) stockholders decide at the 2026 annual meeting?

PMV Pharmaceuticals stockholders elected two Class III directors, approved executive compensation on a non-binding advisory basis, and ratified Ernst & Young LLP as independent auditor for 2026. Each proposal received majority support based on votes cast at the virtual 2026 annual meeting.

Which directors were elected at PMV Pharmaceuticals’ 2026 annual meeting and for how long?

Stockholders elected David H. Mack, Ph.D. and Laurie Stelzer as Class III directors. Each will serve until PMV Pharmaceuticals’ 2029 annual meeting of stockholders, and until a successor is duly elected and qualified or earlier death, resignation, or removal under the company’s governance framework.

How did PMV Pharmaceuticals (PMVP) stockholders vote on executive compensation in 2026?

Stockholders approved the compensation of PMV Pharmaceuticals’ named executive officers on a non-binding advisory basis. The vote totals were 15,015,578 for, 6,468,718 against, 458,072 abstentions and 6,975,412 broker non-votes, reflecting majority support for the pay program described in the April 22, 2026 proxy statement.

Which auditing firm did PMV Pharmaceuticals stockholders ratify for fiscal 2026?

Stockholders ratified Ernst & Young LLP as PMV Pharmaceuticals’ independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification received 28,379,108 votes for, 536,302 against and 2,370 abstentions, indicating strong support for the Audit Committee’s auditor selection.

How often does PMV Pharmaceuticals hold advisory votes on executive compensation?

PMV Pharmaceuticals conducts non-binding advisory votes on executive compensation every year. This annual policy followed stockholder approval of the frequency at the 2022 annual meeting and will remain in effect until the next frequency vote, expected at the company’s 2028 annual meeting of stockholders.

What were the broker non-vote totals at PMV Pharmaceuticals’ 2026 annual meeting?

Broker non-votes totaled 6,975,412 shares on the director elections and the advisory vote on executive compensation. There were no broker non-votes reported on the ratification of Ernst & Young LLP, which received votes classified only as for, against, or abstain.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB